Beranda › Kanker Payudara Triple-Negatif › North Carolina › Durham
Uji klinis Kanker Payudara Triple-Negatif di Durham, NC
12 studi untuk Kanker Payudara Triple-Negatif mencari peserta di lokasi sekitar Durham (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- Duke University, Durham
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Menerima pesertaFase 2
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi jauhnya
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Menerima pesertaFase 3
- Duke Cancer Institute, Durham
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Menerima pesertaFase 2
- Duke University, Durham
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Menerima pesertaFase 2/3
- Duke Cancer Institute, Durham
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Menerima pesertaFase 2
- Duke University Medical Center, Durham
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
Menerima pesertaFase 1
- University of North Carolina, Chapel Hill · 10 mi jauhnya
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Menerima pesertaFase 1
- Duke Cancer Institute /ID# 276267, Durham
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Menerima pesertaFase 2
- The University of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauhnya
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
Menerima pesertaFase 2
- University of North Carolina, Chapel Hill · 10 mi jauhnya
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
Menerima pesertaFase 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
A Study of NX-1607 in Adults With Advanced Malignancies
Menerima pesertaFase 1
- University of North Carolina, Chapel Hill · 10 mi jauhnya
Uji klinis Kanker Payudara Triple-Negatif di kota lain
- Houston, TX42 studi
- New York City, NY31 studi
- Nashville, TN28 studi
- Los Angeles, CA27 studi
- Boston, MA26 studi
- San Antonio, TX23 studi
- St. Louis, MO21 studi
- Arlington, VA20 studi
- Atlanta, GA20 studi
- Dallas, TX18 studi
- Chicago, IL16 studi
- Columbus, OH16 studi
Studi lain di Durham
- Kanker Payudara64 studi
- Kanker (semua jenis)58 studi
- Kanker Paru Non-Sel Kecil39 studi
- Mieloma Multipel37 studi
- Leukemia Mieloid Akut33 studi
- Kanker Metastatik33 studi
- Kanker Prostat32 studi
- Kanker Paru32 studi
- Kanker Kolorektal28 studi
- Kanker Ovarium27 studi
- Leukemia Limfositik Kronis27 studi
- Gagal Jantung26 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.